Published in Rev Bras Psiquiatr on September 01, 2011
Glutamate neurocircuitry: theoretical underpinnings in schizophrenia. Front Pharmacol (2012) 0.94
Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis. Ann Intern Med (2012) 2.52
Modeling sensitization to stimulants in humans: an [11C]raclopride/positron emission tomography study in healthy men. Arch Gen Psychiatry (2006) 1.78
Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry (2008) 1.64
Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial. JAMA Psychiatry (2013) 1.56
Neuroimaging in social anxiety disorder: a systematic review of the literature. Prog Neuropsychopharmacol Biol Psychiatry (2010) 1.55
Functional neuroimaging of minocycline's effect in a patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2010) 1.43
Bioactive contaminants leach from disposable laboratory plasticware. Science (2008) 1.42
Is the full version of the AUDIT really necessary? Study of the validity and internal construct of its abbreviated versions. Alcohol Clin Exp Res (2010) 1.24
Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol (2012) 1.19
Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes (2008) 1.19
Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model. Hum Mol Genet (2009) 1.18
Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab (2008) 1.08
Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol (2006) 1.08
Impaired neurosteroid synthesis in multiple sclerosis. Brain (2011) 1.05
Mood-elevating effects of d-amphetamine and incentive salience: the effect of acute dopamine precursor depletion. J Psychiatry Neurosci (2007) 1.03
Altered gray matter morphometry and resting-state functional and structural connectivity in social anxiety disorder. Brain Res (2011) 1.03
Monoamine oxidase inhibition during brain development induces pathological aggressive behavior in mice. Biol Psychiatry (2002) 1.03
Adhesio interthalamica alterations in schizophrenia spectrum disorders: A systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry (2011) 1.03
Age and gender influence on maximal bite force and masticatory muscles thickness. Arch Oral Biol (2010) 1.01
The antipsychotic potential of l-stepholidine--a naturally occurring dopamine receptor D1 agonist and D2 antagonist. Psychopharmacology (Berl) (2008) 1.00
Decreasing amphetamine-induced dopamine release by acute phenylalanine/tyrosine depletion: A PET/[11C]raclopride study in healthy men. Neuropsychopharmacology (2004) 1.00
Glutamate system, amyloid ß peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology. J Psychiatry Neurosci (2013) 0.99
Genetic inactivation of D-amino acid oxidase enhances extinction and reversal learning in mice. Learn Mem (2008) 0.98
Glia contribute to the purinergic modulation of inspiratory rhythm-generating networks. J Neurosci (2010) 0.98
[Therapeutical use of the cannabinoids in psychiatry]. Rev Bras Psiquiatr (2010) 0.98
Determination of d-serine and related neuroactive amino acids in human plasma by high-performance liquid chromatography with fluorimetric detection. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 0.98
Evaluation of a behavioural weight management programme for patients with severe mental illness: 3 year results. Hum Psychopharmacol (2005) 0.98
Seeing with the eyes shut: neural basis of enhanced imagery following Ayahuasca ingestion. Hum Brain Mapp (2011) 0.97
Glial fibrillary acidic protein and glutamine synthetase in subregions of prefrontal cortex in schizophrenia and mood disorder. Neurosci Lett (2006) 0.96
Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry (2002) 0.95
Are cavum septum pellucidum abnormalities more common in schizophrenia spectrum disorders? A systematic review and meta-analysis. Schizophr Res (2010) 0.94
Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci (2003) 0.93
Noradrenergic and serotonergic neuroendocrine responses in prepubertal, peripubertal, and postpubertal rats pretreated with desipramine and sertraline. J Am Acad Child Adolesc Psychiatry (2002) 0.92
Synthesis, transport, and metabolism of serotonin formed from exogenously applied 5-HTP after spinal cord injury in rats. J Neurophysiol (2013) 0.91
Drug-induced supersensitivity psychosis revisited: characteristics of relapse in treatment-compliant patients. Ther Adv Psychopharmacol (2012) 0.90
Neuroimaging in specific phobia disorder: a systematic review of the literature. Rev Bras Psiquiatr (2012) 0.89
Social anxiety disorder women easily recognize fearfull, sad and happy faces: the influence of gender. J Psychiatr Res (2009) 0.89
A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Curr Pharm Des (2012) 0.89
The antidepressant phenelzine protects neurons and astrocytes against formaldehyde-induced toxicity. J Neurochem (2010) 0.89
Validation of the Investigator's Assessment Questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder. Psychiatry Res (2005) 0.88
D-serine and schizophrenia: an update. Expert Rev Neurother (2012) 0.88
Impaired hippocampal LTP in inbred mouse strains can be rescued by beta-adrenergic receptor activation. Eur J Neurosci (2007) 0.87
Increased glutamate levels in the medial prefrontal cortex in patients with postpartum depression. Neuropsychopharmacology (2012) 0.87
Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study. J Clin Psychopharmacol (2016) 0.86
Relationship of plasma amphetamine levels to physiological, subjective, cognitive and biochemical measures in healthy volunteers. Hum Psychopharmacol (2003) 0.86
The MAO inhibitor phenelzine improves functional outcomes in mice with experimental autoimmune encephalomyelitis (EAE). Brain Behav Immun (2011) 0.85
Do psychiatric comorbidities predict postoperative seizure outcome in temporal lobe epilepsy surgery? Epilepsy Behav (2009) 0.85
Validity of the PHQ-2 for the screening of major depression in Parkinson's disease: two questions and one important answer. Aging Ment Health (2011) 0.85
Increased cholesterol levels during paroxetine administration in healthy men. J Clin Psychiatry (2003) 0.85
Paroxetine-induced increase in metabolic end products of nitric oxide. J Clin Psychopharmacol (2003) 0.84
Neurosteroid-mediated regulation of brain innate immunity in HIV/AIDS: DHEA-S suppresses neurovirulence. FASEB J (2012) 0.84
The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects. Prog Neuropsychopharmacol Biol Psychiatry (2010) 0.84
Effect of D-amphetamine on inhibition and motor planning as a function of baseline performance. Psychopharmacology (Berl) (2010) 0.84
Neurochemical effects of the monoamine oxidase inhibitor phenelzine on brain GABA and alanine: A comparison with vigabatrin. J Pharm Pharm Sci (2008) 0.84
An update on amine oxidase inhibitors: multifaceted drugs. Prog Neuropsychopharmacol Biol Psychiatry (2013) 0.82
Multiple 5-HT receptors are involved in the effects of acute MDMA treatment: studies on locomotor activity and responding for conditioned reinforcement. Psychopharmacology (Berl) (2002) 0.82
The effects of a low protein diet on amino acids and enzymes in the serine synthesis pathway in mice. Amino Acids (2009) 0.81
Fluoxetine, but not sertraline or citalopram, potentiates the locomotor stimulant effect of cocaine: possible pharmacokinetic effects. Psychopharmacology (Berl) (2004) 0.81
The fast alcohol screening test (FAST) is as good as the AUDIT to screen alcohol use disorders. Subst Use Misuse (2010) 0.81
Role of serotonin (5-HT) in the antidepressant-like properties of neuropeptide Y (NPY) in the mouse forced swim test. Peptides (2005) 0.81
Paroxetine-induced increase in metabolic end products of nitric oxide. J Clin Psychopharmacol (2003) 0.81
Neuroactive steroids and anxiety disorders. J Psychiatry Neurosci (2002) 0.81
Charcot-Marie-Tooth disease, psychiatric indicators and quality of life: a systematic review. ASN Neuro (2014) 0.80
Determination of L-serine-O-phosphate in rat and mouse brain tissue using high-performance liquid chromatography and fluorimetric detection. Anal Biochem (2010) 0.80
Rimonabant effects on anxiety induced by simulated public speaking in healthy humans: a preliminary report. Hum Psychopharmacol (2013) 0.80
Zero net flux estimates of septal extracellular glucose levels and the effects of glucose on septal extracellular GABA levels. Eur J Pharmacol (2009) 0.80
Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders? J Psychiatry Neurosci (2007) 0.80
Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD). Rev Bras Psiquiatr (2010) 0.80
Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychopharmacol (2009) 0.80
Monoamine oxidase inhibitors and neuroprotection: a review. Am J Ther (2012) 0.80
Supportive text messages to reduce mood symptoms and problem drinking in patients with primary depression or alcohol use disorder: protocol for an implementation research study. JMIR Res Protoc (2015) 0.79
Agomelatine in the treatment of social anxiety disorder. Prog Neuropsychopharmacol Biol Psychiatry (2010) 0.79
Optimizing antidepressant treatment: efficacy and tolerability. Int Clin Psychopharmacol (2002) 0.79
Gender differences and the effects of ketamine in healthy volunteers. J Psychopharmacol (2004) 0.79
Effects of the antidepressant/antipanic drug phenelzine and its putative metabolite phenylethylidenehydrazine on extracellular gamma-aminobutyric acid levels in the striatum. Biochem Pharmacol (2002) 0.79
Effect of lamotrigine on plasma GABA levels in healthy humans. Prog Neuropsychopharmacol Biol Psychiatry (2003) 0.79
HIV protease inhibitors disrupt astrocytic glutamate transporter function and neurobehavioral performance. AIDS (2016) 0.79
Quantification of l-stepholidine in rat brain and plasma by high performance liquid chromatography combined with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 0.79
[Cannabis sativa: the plant that can induce unwanted effects and also treat them]. Rev Bras Psiquiatr (2010) 0.78
Marijuana, feijoada and the debate on drug legalization. Front Psychiatry (2013) 0.78
Interictal SPECT in patients with mesial temporal lobe epilepsy and psychosis: a case-control study. Psychiatry Res (2005) 0.78
L-Serine-O-phosphate in the central nervous system. Brain Res (2009) 0.78
The pharmacology and formulation of paliperidone extended release. Expert Rev Neurother (2012) 0.78
Tissue concentration changes of amino acids and biogenic amines in the central nervous system of mice with experimental autoimmune encephalomyelitis (EAE). Neurochem Int (2011) 0.78
Individual differences in frontal cortical thickness correlate with the d-amphetamine-induced striatal dopamine response in humans. J Neurosci (2013) 0.78
Recent developments in the regulation of monoamine oxidase form and function: is the current model restricting our understanding of the breadth of contribution of monoamine oxidase to brain [dys]function? Curr Top Med Chem (2012) 0.77
Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats. J Psychopharmacol (2013) 0.77
Monoamine oxidase inhibitors, their structural analogues, and neuroprotection. Indian J Exp Biol (2004) 0.77
The MAO inhibitor phenelzine can improve functional outcomes in mice with established clinical signs in experimental autoimmune encephalomyelitis (EAE). Behav Brain Res (2013) 0.77
Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition. Neurochem Res (2007) 0.77
Late-onset social anxiety disorder following traumatic brain injury. Brain Inj (2012) 0.77
The effects of chronic administration of inhibitors of flavin and quinone amine oxidases on imidazoline I(1) receptor density in rat whole brain. Ann N Y Acad Sci (2003) 0.77
The effects of sodium nitroprusside treatment on cognitive deficits in schizophrenia: a pilot study. J Clin Psychopharmacol (2015) 0.77
Nitric oxide plasma/serum levels in patients with schizophrenia: a systematic review and meta-analysis. Rev Bras Psiquiatr (2012) 0.77